Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with and without AS03 adjuvant

H5N1 influenza vaccine is known to induce diminished antibody responses in vaccine recipients without the use of adjuvant. We hypothesize that this is due to intrinsic defects in innate responses that could explain the poor immunogenicity of the vaccine. These innate responses may be improved with use of an adjuvant, e.g., AS03. Single site, Phase II randomized (2:1) double blinded study in which adult healthy subjects will receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant or Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days (+/- 3 days) apart.